Engflag

Semi AMARYL

Quick links to important sections

Semi AMARYL

Semi AMARYL_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Semi AMARYL

Quick Facts

Property Description
Active ingredient Glimepiride
Form Oral Tablet (Low-dose preparation)
Pharmacological class Antidiabetic Agent (Sulfonylurea Class)
Common use Glycemic control in Type 2 Diabetes Mellitus
Origin Synthetic compound

What Type of Medicine is Semi AMARYL (Glimepiride)?

Semi AMARYL is a specific prescription-only oral preparation containing the active chemical substance Glimepiride. The drug is formally classified as an Antidiabetic Agent belonging to the Sulfonylurea class. Glimepiride is a synthetic compound, chemically derived from sulfonylurea, and is clinically recognized as a third-generation agent within this class. Its pharmacological profile demonstrates focused action as an insulin secretagogue.

This designation confirms the drug's core action: actively increasing the circulating levels of insulin, a process essential for patients with remaining pancreatic function. This preparation is a single-ingredient product, containing Glimepiride as its sole active compound, and is positioned specifically for the initial or maintenance phases of therapy where precise titration is required.

Composition, Form, and General Purpose

The preparation is formulated as an Oral Tablet, providing a straightforward solid pharmaceutical form for administration. Its composition includes only Glimepiride alongside solid pharmaceutical excipients. The specific inclusion of "Semi" in the product name signifies a low-dose preparation variant relative to the standard tablet strength, differentiating it from higher-strength forms. This lower strength provides necessary clinical flexibility, often utilized for starting treatment in adult patients with Type 2 diabetes mellitus.

The general purpose of this oral hypoglycemic agent is to achieve effective, sustained glycemic control by assisting the body in managing chronically elevated blood sugar levels, or hyperglycemia. By supporting the body’s internal mechanisms for regulating insulin, the medication aids in establishing metabolic balance. This is vital for managing the chronic nature of Type 2 diabetes, such as when diet and exercise alone are insufficient to maintain target blood sugar levels.

Regulatory References

  1. Glimepiride - StatPearls (NIH)

What side effects are possible with Semi AMARYL?

The safety profile of Glimepiride (Semi AMARYL) is defined by officially documented adverse effects and safety constraints, primarily based on classifications from government regulatory bodies.

Adverse Reaction Scope

Category Details (Regulatory Terminology)
Most Common Risk Hypoglycemia (low blood sugar), classified as Common (1/100), which is an expected effect of the drug class.
Key System-Organ Classes Blood and Lymphatic System Disorders, Gastrointestinal Disorders (e.g., Nausea, Diarrhea), Hepato-biliary Disorders, and Immune System Disorders.
Rare Adverse Reactions Blood disorders (e.g., Thrombocytopenia, Leukopenia), Allergic vasculitis, and Very Rare incidents of severe hepatic impairment and Hyponatremia.
Serious Reactions Officially documented severe adverse reactions include severe Hypoglycemia (potential for coma/seizures), Agranulocytosis, Pancytopenia, and life-threatening Anaphylactic Reactions.

Official Safety Constraints and Populations

Glimepiride is officially contraindicated in patients with a history of hypersensitivity to the active substance, other Sulfonylureas, or Sulfonamide derivatives, and in severe Renal or Hepatic function disorders. The label notes that Older Adults and patients with impaired renal or hepatic function are at increased risk for hypoglycemia. Safety and efficacy are not established for pediatric patients. Time-related patterns state that hypoglycemia and transient visual disturbances are more likely to occur at the start of treatment or following dose changes.

Regulatory Safety Summary

The regulatory safety summary is structurally built around the primary risk of hypoglycemia as a common event. The profile utilizes System-Organ-Class groupings to map the full range of officially listed effects. Regulatory documentation defines key safety limitations by explicitly listing severe conditions and patient populations for whom the medication is contraindicated.

Overdose and Emergency Response

Overdose and when to seek help

Overdosage with Semi AMARYL is formally documented in regulatory labeling to result in profound and prolonged severe hypoglycemia (low blood sugar), which is a direct metabolic crisis. This state can rapidly lead to critical neurological and systemic manifestations. The documented clinical signs of overdose-induced hypoglycemia include a range of symptoms such as confusion, shakiness, anxiety, cold sweats, slurred speech, and blurred vision.

Severe manifestations may progress to convulsions, unconsciousness (coma), and carry the potential for permanent brain function impairment or death. For these reasons, a severe hypoglycemic reaction constitutes a medical emergency requiring immediate treatment.

Individuals must contact emergency services if the person has collapsed, had a seizure, or cannot be awakened. Management of the severe event is officially described to require the administration of intravenous glucose (dextrose) and other supportive measures. Continued hospital observation is required due to the officially recognized risk that hypoglycemia may recur after initial apparent clinical recovery. Regulatory documentation specifies that patients who are elderly or have renal or hepatic impairment are particularly susceptible to the severe effects of overdosage.

Therapeutic Uses of Semi AMARYL

What Semi AMARYL Treats: Main Uses and Benefits

Semi AMARYL (Glimepiride) is used for the long-term management of Type 2 Diabetes Mellitus, primarily to address symptoms related to systemic imbalance, specifically chronic hyperglycemia. The drug is used as an adjunct to diet and exercise to improve glycemic control in adults with this condition.

Quick Fact: Support for Chronically Elevated Blood Glucose

The medication is applied in addressing elevated clinical markers of diabetes related to systemic imbalance. It is generally relevant for easing the pronounced physiological strain caused by uncontrolled blood sugar. This supportive therapeutic benefit assists with maintaining functional stability and contributes to easing the overall symptom load when lifestyle measures alone are no longer sufficient.

The medication is commonly used across conditions presenting with episodic or fluctuating manifestations of blood sugar. In essence, the drug plays a role in managing the primary therapeutic goals: “It supports patients during difficult episodes by helping maintain a sense of long-term metabolic stability.” The sustained management of these clinical markers is applicable within clinical settings that involve acute or disruptive symptom patterns of poor glucose control, offering essential support when the chronic condition becomes more noticeable.

Regulatory References

  1. Official DailyMed Labeling from NIH

Eligibility and Restrictions for Use

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults with Type 2 Diabetes Mellitus only.
Populations for whom use is contraindicated Patients with Type 1 diabetes mellitus or diabetic ketoacidosis; history of hypersensitivity to Glimepiride or sulfonamide derivatives; severe hepatic or severe renal function disorders.
Populations for whom use is not recommended Pediatric patients (under 18 years) as safety and effectiveness are not established; women who are pregnant or breastfeeding.

Official Eligibility Structure

Age-Related Rules

Use is not recommended for children and adolescents due to insufficient data. The elderly population is permitted use, but they are recognized as being at an increased risk for hypoglycemia, necessitating caution.

Condition-Specific Limitations

Absolute contraindications include severe impairment of liver or kidney function. Caution is required for patients with less severe renal impairment, adrenal or pituitary insufficiency, G6PD deficiency, or for those who are debilitated or malnourished. The official use of this medicine is therefore rigidly limited to adults with Type 2 diabetes who do not possess the documented exclusion criteria.

What should I know about interactions with other medicines?

Semi AMARYL (glimepiride) may interact with a wide range of other medications, potentially causing either an increase or a decrease in its blood-glucose-lowering effect. These interactions can lead to dangerously low blood sugar (hypoglycemia) or, conversely, a loss of blood sugar control (hyperglycemia).

Interactions that May Increase Hypoglycemia Risk (Potentiation)

Certain drug classes can enhance the effect of Semi AMARYL, requiring close blood glucose monitoring and potential dose adjustment:

  • Other Antidiabetics: Including insulin, metformin, and other oral agents.
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Such as ibuprofen and certain anti-inflammatory pain relievers.
  • Angiotensin-Converting Enzyme (ACE) Inhibitors: Medications used for blood pressure and heart conditions.
  • Some Antibiotics and Antifungals: Including certain sulfonamides, clarithromycin, and fluconazole.
  • Alcohol: Consumption of alcohol can unpredictably intensify the glucose-lowering action.

Interactions that May Decrease Efficacy (Attenuation)

Other medications may reduce the blood-sugar-lowering effect of Semi AMARYL, potentially leading to high blood sugar. These include:

Drug Class Examples
Corticosteroids Prednisone
Thiazide Diuretics Hydrochlorothiazide
Thyroid Hormones Levothyroxine
Atypical Antipsychotics Olanzapine

Important Considerations

  • Colesevelam: This cholesterol-lowering agent reduces glimepiride absorption. Semi AMARYL must be taken at least four hours before a dose of colesevelam to minimize this interaction.
  • Beta-Blockers and Clonidine: These medications can mask the typical warning signs of low blood sugar, such as a rapid heart rate, making hypoglycemia harder to detect and treat promptly.
  • Herbal and Dietary Supplements: Always inform your doctor or pharmacist about all over-the-counter medicines, vitamins, and herbal products you are using, as they may also cause interactions.

Mechanism of Action

How Semi AMARYL Works

Directly Triggering Insulin Secretion

The drug's primary action is achieved through the inhibition of ATP-sensitive Potassium ( K ATP) channels located on the pancreatic beta-cell membrane. Glimepiride binds to the Sulfonylurea Receptor 1 ( SUR1) subunit, which forces the channel to close and prevents the efflux of K^+ ions. This molecular event causes membrane depolarization, which subsequently opens voltage-gated Ca^2+ channels. The resultant influx of Ca^2+ ions directly triggers the exocytosis of stored insulin granules, increasing the circulating insulin concentration.

Modulating Peripheral Glucose Uptake

Glimepiride also exhibits an extrapancreatic effect that modulates the efficiency of glucose absorption in peripheral tissues. The mechanism promotes the translocation of Glucose Transporter Type 4 ( GLUT4) proteins from the intracellular space to the plasma membrane of skeletal muscle and adipose cells. This action facilitates glucose uptake, which coordinates with the effect of the newly released insulin. This primary mechanism requires the presence of residual, functional beta-cells to stimulate insulin release.

Dosage and Administration Information

The administration of Glimepiride, the active substance in Semi AMARYL, is governed by a defined protocol for long-term use in managing blood sugar. The medication is an oral tablet that is taken once daily. To ensure consistent administration, the dose must be ingested specifically with breakfast or the first main meal of the day.

The initial adult dosing regimen typically begins with a low dose of 1 mg or 2 mg once daily. Dosing adjustments, or titration, are executed gradually; subsequent increases are applied in increments of 1 mg or 2 mg but only after assessing the patient’s response over an interval of at least one to two weeks. Dosing recommendations for the maximum daily intake may vary by region, with limits generally set at 8 mg once daily in some areas, and often 6 mg once daily in others.

Specific administration rules apply to certain populations. For older adults and patients with renal impairment, the starting dose is typically reduced to 1 mg once daily. If a daily dose is forgotten, the next dose must not be increased to compensate for the missed amount. The tablet must be swallowed whole with liquid and is intended for use as part of a continuous therapeutic plan.

Recent Clinical Evidence

Research evidence / Overview of studies for Semi AMARYL

Evidence for use in Type 2 Diabetes Mellitus

Studies for Semi AMARYL primarily involve randomized controlled trials and large observational studies. These trials were designed to examine outcomes related to systemic or functional imbalance, such as changes in the long-term blood sugar marker ( HbA1c) and daily measures of glucose. The research focused on adult patients with Type 2 Diabetes Mellitus.

Research highlights changes measured during the study period, as studies tracked measurements of blood glucose and HbA1c levels. Findings describe patterns observed in the studies regarding the occurrence of low blood sugar events. Uncertainty remains concerning the long-term evolution of these measured changes beyond the intermediate follow-up periods, and data are still emerging for specific patient groups with complex health issues.

Evidence for use in Established Cardiovascular Disease

Evidence for this indication primarily comes from large, multi-year studies that monitored major adverse cardiovascular events ( MACE). The studies explored endpoints such as the first occurrence of events like heart attack, stroke, and hospitalization for heart failure in patients with Type 2 Diabetes Mellitus who had established cardiovascular disease or were considered at high risk.

Studies monitored the time and rate at which these major cardiovascular events occurred across the observed populations. A specific area of uncertainty involves the limited long-term data on cardiovascular outcomes in patient populations that do not have Type 2 Diabetes. The results apply only to the populations studied, which were overwhelmingly adults with co-existing Type 2 Diabetes.

Evidence for use in Chronic Kidney Disease

Research examined outcomes related to kidney function, specifically tracking the progression of kidney function decline ( eGFR) and changes in markers of kidney damage. Research describes patterns in the observed incidence of reaching composite endpoints (combining several measures of worsening kidney health) in patients with CKD associated with diabetes.

Uncertainty remains because data for certain groups, such as patients with very advanced Chronic Kidney Disease, remain insufficient, as these individuals were typically excluded from the main trials.

Frequently Asked Questions (FAQ)

Common questions about Semi AMARYL (FAQ)

Q: What specific instructions apply to taking Semi AMARYL with respect to food?

A: Official product information states that Semi AMARYL should be taken with breakfast or the first main meal of the day. This timing helps to align the medication's effects with the body's natural processes of handling food.

Q: Can I split or chew the Semi AMARYL tablet?

A: Regulatory instructions for Semi AMARYL state that the tablet must be swallowed whole with liquid. The medication is not intended to be crushed, split, or chewed, as the tablet is designed to be swallowed whole.

Q: What should I do if I forget to take my daily dose?

A: If a dose is forgotten, regulatory documentation instructs that the subsequent dose must not be increased to try and make up for the missed amount. Official documentation indicates that increasing the next dose could heighten the risk of low blood sugar.

Q: How long does it typically take for Glimepiride to start working after the first dose?

A: According to the official product information on how the medicine is processed by the body, a mild blood sugar-lowering effect typically starts to appear within two to three hours after taking the first dose. This timeline corresponds with the drug's peak concentration in the blood.

Q: Can Semi AMARYL be taken with Colesevelam?

A: Yes, Semi AMARYL can be taken with Colesevelam, a cholesterol-lowering medication, but the timing of the two medications should be separated. Official drug interaction warnings recommend that Semi AMARYL be taken at least four hours prior to a dose of Colesevelam. This separation is recommended by the label to minimize the chance that the cholesterol medicine interferes with the absorption of Semi AMARYL.

Q: What is the storage temperature requirement for Semi AMARYL?

A: Regulatory stability guidelines indicate that Semi AMARYL should be stored below a specific maximum temperature, which is either 30 C or 25 C, as stated on the specific package label. Additionally, the drug must be kept protected from light and moisture.

Q: Are there any known effects of Glimepiride on weight gain or loss?

A: Studies and official information indicate that weight gain is noted as a potential side effect associated with the class of medications Glimepiride belongs to (sulfonylureas). Weight changes have been observed in clinical trials for specific patient groups using Glimepiride.

Q: What are the symptoms of low blood sugar (hypoglycemia)?

A: While a full list of signs is not explicitly provided in the core label, regulatory warnings about low blood sugar (hypoglycemia) emphasize that a patient’s ability to concentrate and react may be impaired. This impairment is noted in regulatory warnings as a key safety concern.

Q: Is it necessary to monitor blood sugar at home while taking this medication?

A: Due to the primary safety risk of low blood sugar, official prescribing information states that patients must be educated to recognize and manage hypoglycemia. The safety information highlights the importance of recognizing and addressing low blood sugar events.

How should Semi AMARYL be stored and disposed of?

Storage and Disposal Instructions for Semi AMARYL (Glimepiride)

Official regulatory guidelines define specific conditions that must be followed to maintain the product's stability and integrity.

Mandatory Storage Conditions

Requirement Specific Condition
Temperature Must be stored below a maximum limit, typically 30 C or 25 C, as specified on the package label.
Protection Must be protected from light and moisture.
Container Rule Must be kept in the original container until use.
Child Safety Must be stored out of the sight and reach of children.

Stability and Disposal

The medicine is stable for its labeled shelf-life (e.g., 3 years or 30 months) when stored according to these conditions. Disposal of any unused or expired Glimepiride must be conducted in accordance with local requirements for pharmaceutical waste, as mandated by the regulatory labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Semi AMARYL found in:

A-Z Index: